Journal article icon

Journal article

Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age

Abstract:
Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a ‘toddler’ booster dose are essential to optimise vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vacc... Expand abstract
Publication status:
Accepted
Peer review status:
Peer reviewed
Version:
Accepted Manuscript

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Surgical Sciences
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Paediatrics
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Primary Care Health Sciences
Expand authors...
Novartis Vaccines and Diagnostics More from this funder
Publisher:
Lippincott, Williams and Wilkins Publisher's website
Journal:
Pediatric Infectious Disease Journal Journal website
Publication date:
2015
DOI:
ISSN:
1532-0987
URN:
uuid:6dc5c441-f1a6-410c-8de9-fcd457da57b2
Source identifiers:
574337
Local pid:
pubs:574337

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP